890 related articles for article (PubMed ID: 12000207)
1. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
Feighner JP; Overø K
J Clin Psychiatry; 1999 Dec; 60(12):824-30. PubMed ID: 10665628
[TBL] [Abstract][Full Text] [Related]
3. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Bielski RJ; Ventura D; Chang CC
J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
[TBL] [Abstract][Full Text] [Related]
4. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
5. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
6. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
[TBL] [Abstract][Full Text] [Related]
10. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Lepola UM; Loft H; Reines EH
Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
Stahl SM; Gergel I; Li D
J Clin Psychiatry; 2003 Nov; 64(11):1322-7. PubMed ID: 14658946
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
15. Escitalopram continuation treatment prevents relapse of depressive episodes.
Rapaport MH; Bose A; Zheng H
J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
Davidson JR; Bose A; Korotzer A; Zheng H
Depress Anxiety; 2004; 19(4):234-40. PubMed ID: 15274172
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.
Kim JM; Bae KY; Stewart R; Jung BO; Kang HJ; Kim SW; Shin IS; Hong YJ; Kim JH; Shin HY; Kang G; Ahn Y; Kim JK; Jeong MH; Yoon JS
J Clin Psychiatry; 2015 Jan; 76(1):62-8. PubMed ID: 25375836
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Wade A; Michael Lemming O; Bang Hedegaard K
Int Clin Psychopharmacol; 2002 May; 17(3):95-102. PubMed ID: 11981349
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
